TG THERAPEUTICS, INC.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $616.3M | $329.0M | $233.7M | $2.8M | $6.7M |
| Operating income | $123.3M | $41.9M | $20.6M | -$218.3M | -$344.8M |
| Operating expenses | — | — | — | $195.6M | $351.5M |
| Cost of revenue | $100.7M | $38.5M | $14.1M | $265,000 | $790,000 |
| Cash from operations | -$24.8M | -$40.5M | -$31.4M | -$176.2M | -$295.6M |
| Capital expenditure | $214,000 | $45,000 | $0 | $14,000 | $401,000 |
| Free cash flow | -$25.0M | -$40.6M | -$31.4M | -$176.2M | -$296.0M |
| Share repurchases | $91.2M | $8.8M | $0 | $0 | — |
| Impairments | — | — | — | $0 | $0 |
| Total assets | $1.1B | $577.7M | $329.6M | $193.6M | $379.6M |
| Total liabilities | $415.2M | $355.3M | $169.1M | $135.0M | $142.5M |
| Total debt | — | — | $105.2M | $76.7M | — |
Shares outstanding 153.1M · Free float 78.9%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.